Condition
Systemic Treatments
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Unknown2
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07476807Not ApplicableEnrolling By Invitation
Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
NCT05535829Unknown
Molecular Markers in Predicting Response to Treatment in FH-deficient RCC Patients
NCT05243173Unknown
Biomarkers of Response to Systemic Treatments in FH-deficient RCC
Showing all 3 trials